采用全身性磷酸二酯酶5和磷酸二酯酶6抑制剂（西地那非）治疗中心性浆液性脉络膜视网膜病变。
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).
作者信息
Coleman D Jackson, Lee Winston, Daly Suzanne, Breazzano Mark P, Sparrow Janet, Tsang Stephen H
机构信息
Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.
Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia Stem Cell Initiative, Departments of Ophthalmology, Pathology & Cell Biology, Institute of Human Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA.
出版信息
Am J Ophthalmol Case Rep. 2020 Dec 3;21:100998. doi: 10.1016/j.ajoc.2020.100998. eCollection 2021 Mar.
PURPOSE
Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR).
OBSERVATIONS
In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy.
CONCLUSIONS
AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments.
目的
研究全身性磷酸二酯酶抑制（西地那非）用于清除中心性浆液性脉络膜视网膜病变（CSCR）的效果。
观察结果
在一名病程较长的CSCR患者中，西地那非使病情迅速缓解。停药（撤药）后，CSCR复发。再次用药时，CSCR再次迅速消失，且在持续治疗的5个月中未复发。
结论及重要性
全身性西地那非可使CSCR迅速清除，可增强或替代其他治疗方法。
Zotero 插件